In recent trading, shares of Aclaris Therapeutics Inc (ACRS) have crossed above the average analyst 12-month target price of $26.67, changing hands for $26.79/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..